Sanofi considers acquiring Insmed to diversify amid Dupixent patent expiration
Sanofi is considering acquiring Insmed Inc. to diversify its portfolio as its blockbuster drug Dupixent faces patent expiration. Insmed's strong respiratory products, like Brinsupri and Arikayce, preโฆ
Insmed Inc. saw its stock price soar on Thursday after reports emerged that French pharmaceutical company Sanofi is considering acquiring the respiratory disease specialist. This potential acquisition comes as Sanofi, under new CEO Belรฉn Garijo, seeks to diversify its portfolio and reduce its dependence on its blockbuster drug Dupixent, which is facing patent expiration.
Sanofi's interest in Insmed reflects a broader trend in the pharmaceutical industry where companies are actively seeking new growth opportunities amid increasing competition and the looming loss of exclusivity on key products. Dupixent has been a significant revenue driver for Sanofi, but as its patent clock ticks down, the company is exploring strategic acquisitions to bolster its future pipeline. According to sources cited in Bloomberg, Sanofi is currently working with financial advisers to assess the potential acquisition of Insmed.
Insmed offers two commercialized respiratory drugs: Brinsupri, which treats non-cystic fibrosis bronchiectasis, and Arikayce, aimed at patients with refractory Mycobacterium avium complex (MAC) lung disease. In the third quarter, Brinsupri alone generated sales of $400.1 million, showcasing its strong market potential. The growth of these products could make Insmed an attractive target for Sanofi as it seeks to expand its respiratory portfolio.
If the acquisition proceeds, it could reshape the competitive landscape in the respiratory market. For Sanofi, acquiring Insmed would mean not only enhancing its product offerings but also gaining access to valuable expertise in respiratory diseases. The move underscores the increasing urgency for pharmaceutical companies to innovate and adapt in a rapidly changing industry.
Read Full Story at Benzinga โ


